Palache Abraham, Oriol-Mathieu Valerie, Abelin Atika, Music Tamara
Abbott, C.J. van Houtenlaan 36, 1381 CP, Weesp, The Netherlands.
Crucell Holland B.V., Newtonweg 1, 2333 CP, P.O. Box 2048, 2301 Leiden, CA, The Netherlands.
Vaccine. 2014 Nov 12;32(48):6369-76. doi: 10.1016/j.vaccine.2014.07.012. Epub 2014 Nov 1.
Globally there are an estimated 3-5 million cases of severe influenza illness every year, resulting in 250,000-500,000 deaths. At the World Health Assembly in 2003, World Health Organization (WHO) resolved to increase influenza vaccine coverage rates (VCR) for high-risk groups, particularly focusing on at least 75% of the elderly by 2010. But systematic worldwide data have not been available to assist public health authorities to monitor vaccine uptake and review progress toward vaccination coverage targets. In 2008, the International Federation of Pharmaceutical Manufacturers and Associations Influenza Vaccine Supply task force (IFPMA IVS) developed a survey methodology to assess global influenza vaccine dose distribution. The current survey results represent 2011 data and demonstrate the evolution of the absolute number distributed between 2004 and 2011 inclusive, and the evolution in the per capita doses distributed in 2008-2011. Global distribution of IFPMA IVS member doses increased approximately 86.9% between 2004 and 2011, but only approximately 12.1% between 2008 and 2011. The WHO's regions in Eastern Mediterranean (EMRO), Southeast Asian (SEARO) and Africa (AFRO) together account for about 47% of the global population, but only 3.7% of all IFPMA IVS doses distributed. While distributed doses have globally increased, they have decreased in EURO and EMRO since 2009. Dose distribution can provide a reasonable proxy of vaccine utilization. Based on the dose distribution, we conclude that seasonal influenza VCR in many countries remains well below the WHA's VCR targets and below the recommendations of the Council of the European Union in EURO. Inter- and intra-regional disparities in dose distribution trends call into question the impact of current vaccine recommendations at achieving coverage targets. Additional policy measures, particularly those that influence patients adherence to vaccination programs, such as reimbursement, healthcare provider knowledge, attitudes, practices, and communications, are required for VCR targets to be met and benefit public health.
全球每年估计有300万至500万例严重流感病例,导致25万至50万人死亡。在2003年世界卫生大会上,世界卫生组织(WHO)决定提高高危人群的流感疫苗接种率(VCR),尤其要在2010年前使至少75%的老年人接种疫苗。但全球范围内缺乏系统数据来协助公共卫生当局监测疫苗接种情况并评估实现疫苗接种覆盖率目标的进展。2008年,国际制药商协会联合会流感疫苗供应特别工作组(IFPMA IVS)制定了一种调查方法来评估全球流感疫苗剂量分布情况。当前的调查结果代表了2011年的数据,展示了2004年至2011年(含)期间分发的绝对数量的变化,以及2008年至2011年期间人均分发剂量的变化。IFPMA IVS成员剂量的全球分发量在2004年至2011年期间增加了约86.9%,但在2008年至2011年期间仅增加了约12.1%。世卫组织东地中海区域(EMRO)、东南亚区域(SEARO)和非洲区域(AFRO)加起来约占全球人口的47%,但在IFPMA IVS分发的所有剂量中仅占3.7%。虽然全球分发剂量有所增加,但自2009年以来,欧洲区域(EURO)和东地中海区域的分发量却有所下降。剂量分布可以合理地代表疫苗使用情况。基于剂量分布,我们得出结论,许多国家的季节性流感VCR仍远低于世界卫生大会的VCR目标,也低于欧盟理事会在欧洲区域的建议。剂量分布趋势在区域间和区域内的差异令人质疑当前疫苗建议在实现覆盖率目标方面的影响。若要实现VCR目标并使公众健康受益,需要采取更多政策措施,特别是那些影响患者对疫苗接种计划依从性的措施,如报销政策、医疗服务提供者的知识、态度、做法及宣传沟通等。